Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases

Annual Review of Microbiology

Volumn 54, Issue , 2000, Pages 19-48

  Khanna, R ^a   Burrows, S R ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Epitope; Immumodulation; Immune escape; Immunotherapy; Latency; Lymphoma

Indexed keywords

AMINO ACID; CYTOKINE; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; VIRUS PROTEIN;

ADAPTATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGEN PRESENTATION; CARCINOGENESIS; CELL INTERACTION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOTHERAPY; LATENT PERIOD; LYMPHOCYTE FUNCTION; LYMPHOMA; MOLECULAR EVOLUTION; MOLECULAR RECOGNITION; NASOPHARYNX CANCER; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PATHOGENESIS;

AMINO ACID SEQUENCE; ANTIGENS, VIRAL; BURKITT LYMPHOMA; CARRIER STATE; EPITOPES; EPSTEIN-BARR VIRUS INFECTIONS; GEOGRAPHY; HUMANS; IMMUNITY, CELLULAR; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 0033758794     PISSN: 00664227     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.micro.54.1.19     Document Type: Review

References (92)

1. Phenotypic analysis of antigen-specific T lymphocytes
2. Sequence variation of cytotoxic T-cell epitopes in different isolates of Epstein-Barr virus
3. Interleukin-10 abrogates the inhibition of Epstein-Barr vires-induced B-cell transformation by memory T-cell responses
4. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing
5. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr vires
6. Etiology of Burkitt's lymphoma - An alternative hypothesis to a vectored virus
7. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: Implications for virus evolution
8. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3
9. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants
10. The specificity of recognition of a cytotoxic T lymphocyte epitope
11. An Epstein-Barr virus-specific cytotoxic T-cell epitope in EBV nuclear antigen 3 (EBNA 3)
12. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis
13. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
14. The biology of Epstein-Barr virus: Lessons learned from the vires and the host
15. Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft
16. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population
17. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin
18. A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes
19. Erratum
20. Dominant cytotoxic T lymphocyte response to the immediate-early trans-activator protein, BZLF1, in persistent type A or B Epstein-Barr virus infection
21. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
22. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease
23. Epstein-Barr virus-transformed human precursor B cell lines: Altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes
24. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T-cell surveillance
25. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation
26. The virus as the etiological agent of infectious mononucleosis
27. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis
28. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis
29. Adoptive cellular immunotheraphy for EBV lymphoproliferative disease
30. Tumour surveillance: Missing peptides and MHC molecules
31. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
32. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line
33. Immune regulation in Epstein-Barr virus-associated diseases
34. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBVassociated malignancies
35. Hierarchy of Epstein-Barr virus-specific cytotoxic Tcell responses in individuals carrying different subtypes of an HLA allele: Implications for epitope-based antiviral vaccines
36. Cytotoxic T-lymphocyte clones specific for an immunodominant epitope display discerning antagonistic response to naturally occurring Epstein-Barr virus variants
37. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA 1- specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing
38. Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: Implications for viral persistence and tumor surveillance
39. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells: Evidence for a critical role for ICAM-2
40. Class I processing defective Burkitt's lymphoma cells are recognised efficiently by CD4+ EBV-specific CTL
41. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): Evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells
42. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells
43. Vaccine strategies against Epstein-Barr vires-associated diseases: Lessons from studies on cytotoxic T-cell mediated immune regulation
44. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression
45. EBV structural antigens, gp350 and gp85, as targets for ex vivo vires-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design
46. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: Influence of peptide conformation and TCR-peptide interaction
47. Evolutionary dynamics of genetic variation in Epstein-Barr vires isolates of diverse geographical origins: Evidence for immune pressure-independent genetic drift
48. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: Analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition
49. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr vires nuclear antigen-1
50. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes
51. Cytotoxic T lymphocyte discrimination between type A Epstein-Barr virus transformants is mapped to an immunodominant epitope in EBNA 3
52. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1
53. T lymphocytes in infectious mononucleosis. I. T-cell death in vitro
54. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea
55. Cytotoxic Tcell clones discriminate between A- and B-type Epstein-Barr vires transformants
56. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes
57. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T-cells in virus-infected leukocyte cultures
58. Paralysis of B7 co-stimulation through the effect of viral IL-10 on T cells as a mechanism of local tolerance induction
59. Counting antigen-specific CD8 T cells: A reevaluation of bystander activation during viral infection
60. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
61. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes
62. Viral strategies of immune evasion
63. Epstein-Barr vires
64. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
65. T-cell-mediated regression of spontaneous and of Epstein-Barr vires-induced B-cell transformation in vitro: Studies with cyclosporin A
66. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance
67. Use of gene-modifled vires-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
68. The ecology and pathology of Epstein-Barr virus
69. A minimal glycinealanine repeat prevents the interaction of ubiquitinated I kappa B alpha with the proteasome: A new mechanism for selective inhibition of proteolysis
70. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection
71. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis
72. Acute infectious mononucleosis stimulates the selective expression/expansion of V beta 6.1-3 and V beta 7 T-cells
73. One step ahead of the game: Viral immunomodulatory molecules
74. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation
75. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
76. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory
77. In vitro expansion of Epstein-Barr vires-specific HLA-restricted cytotoxic T-cells direct from the blood of infectious mononucleosis
78. Multiple HLA class I-dependent cytotoxicities constitute the 'non-HLA-restricted' response in infectious mononucleosis
79. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor
80. Viral interleukin 10 (IL- 10), the human herpes vires 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors
81. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
82. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals
83. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell
84. The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: The early suppression by T cells of Epstein Barr infection is mediated by interferon
85. Suppression of in vitro Epstein-Barr virus infection: A new role for adult human T lymphocytes
86. Characterization of the T-cell-mediated cellular cytotoxicity during acute infectious mononucleosis
87. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells
88. Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: A consequence of immune surveillance or a phenotypic vestige of the progenitor cells?
89. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses
90. Synergistic role of type I interferons in the induction of protective cytotoxic T lymphocytes
91. Recruitment during infectious mononucleosis of CD3+ CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1
92. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10